MGTA Key Statistics, Chart & Performance
The current stock price of MGTA is 0.6996 USD. In the past month the price decreased by -13.09%. In the past year, price decreased by -58.36%.
MGTA Technical Analysis
MGTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGTA. While MGTA has a great health rating, there are worries on its profitability.
MGTA Financial Highlights
Over the last trailing twelve months MGTA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 12.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MGTA Forecast & Estimates
6 analysts have analysed MGTA and the average price target is 1.02 USD. This implies a price increase of 45.8% is expected in the next year compared to the current price of 0.6996.
MGTA Ownership
About MGTA
Company Profile
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Company Info
MAGENTA THERAPEUTICS INC
100 Technology Sq Fl 5
Cambridge MASSACHUSETTS 02139 US
CEO: Jason Gardner
Employees: 67
Phone: 18572012700.0
MAGENTA THERAPEUTICS INC / MGTA FAQ
Can you describe the business of MAGENTA THERAPEUTICS INC?
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
What is the current price of MGTA stock?
The current stock price of MGTA is 0.6996 USD. The price decreased by -7.74% in the last trading session.
What is the dividend status of MAGENTA THERAPEUTICS INC?
MGTA does not pay a dividend.
What is the ChartMill rating of MAGENTA THERAPEUTICS INC stock?
MGTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists MGTA stock?
MGTA stock is listed on the Nasdaq exchange.
What is the market capitalization of MGTA stock?
MAGENTA THERAPEUTICS INC (MGTA) has a market capitalization of 2.65M USD. This makes MGTA a Nano Cap stock.